EP2691135B1 - Metered dose inhaler spacer - Google Patents
Metered dose inhaler spacer Download PDFInfo
- Publication number
- EP2691135B1 EP2691135B1 EP12763707.2A EP12763707A EP2691135B1 EP 2691135 B1 EP2691135 B1 EP 2691135B1 EP 12763707 A EP12763707 A EP 12763707A EP 2691135 B1 EP2691135 B1 EP 2691135B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- receiving chamber
- mdi
- dose
- spacer
- airflow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
- A61M15/0015—Details of inhalators; Constructional features thereof with inhalation check valves located upstream of the dispenser, i.e. not traversed by the product
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0018—Details of inhalators; Constructional features thereof with exhalation check valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3334—Measuring or controlling the flow rate
Definitions
- a Metered Dose Inhaler is a device that, when actuated, emits a measured (metered) dose of an aerosolized medicine for inhalation by a patient. This dose of medicine is designed to be inhaled into the lungs of a user of the MDI.
- An MDI typically includes three portions, a canister for containing the medicine and propellant, an actuator shaft/aerosol nozzle for actuating the canister and metering out the dose, and a mouthpiece.
- the mouthpiece and actuator valve are combined into a single assembly into which the canister is inserted. When the canister is depressed against the actuator valve, a metered dose is emitted from the canister, through the valve and out through the mouthpiece for inhalation by a user of the MDI.
- An MDI spacer is a spacer that goes between the MDI and the mouth of a user of the MDI.
- An MDI spacer allows particles in the aerosolized dose to settle out a bit and mix with air, thus allowing for more effective delivery of a metered dose into a user's lungs when inhaled.
- An MDI spacer assists in preventing a user from inhaling the metered dose directly from an MDI where the dose would be traveling so fast that the particles of the aerosolized spray from the MDI hit and stick to the back of the user's throat rather than being inhaled into the user's lungs where the medicine of the metered dose is designed to be delivered.
- MDI spacer various embodiments of a metered dose inhaler (MDI) spacer are described. The description will begin first with a discussion of the major structural components of an example MDI spacer. Attention will then be directed to sub-components which may be combined in various embodiments or utilized all together in an embodiment. Description of the operation of an example MDI spacer and the various components and sub-components will be further explained in conjunction with discussion of a flow path for a metered dose and inhaled breath, and description of a flow path for exhaled breath.
- MDI spacer description of the operation of an example MDI spacer and the various components and sub-components will be further explained in conjunction with discussion of a flow path for a metered dose and inhaled breath, and description of a flow path for exhaled breath.
- MDI Metered Dose Inhaler
- Figure 1 shows a rear left side perspective of an example MDI spacer 100, according to an example.
- a first set of section indicators indicate the viewing direction of Section A - A, which is illustrated in Figure 4 ; and a second set of section indicators indicate the viewing direction of Section B - B, which is illustrated in Figures 5 and 7 .
- the major components of MDI spacer 100 include: a distal end portion 110, a body 120, a proximal end portion 130, and a mouth port 140. Subcomponents, which are described herein, may be coupled in various combinations with these major components to constitute various examples of the MDI spacers described herein.
- box 150 surrounds a region which is shown in enlarged detail in Figure 3 .
- Body 120 defines a dose receiving chamber 475 ( Figures 4-7 ) which acts as a spacer into which a metered dose is sprayed from an MDI prior to being inhaled into the lungs of a user of MDI spacer 100.
- Body 120 is cylindrically shaped, and the dose receiving chamber 475 that is defined by body 120 is a substantially hollow cylinder within body 120.
- Distal end portion 110 is coupled with a distal end (end farthest from the mouth of a user when MDI spacer 100 is in use) of body 120.
- An opening 113 is defined in distal end portion 110. Opening 113 is sized to receive the mouthpiece of a metered dose inhaler.
- a collar 115 subcomponent may be coupled with distal end portion 110 and disposed within opening 113.
- a combined one-way and flow rate control valve 112 also referred to herein as "valve 112" subcomponent is coupled with distal end portion 110.
- Proximal end portion 130 is coupled with a proximal end (end nearest to the mouth of a user when MDI spacer 100 is in use) of body 120.
- Proximal end portion 130 forms a proximal end of the dose receiving chamber 475.
- Proximal end portion 130 opens into and couples dose receiving chamber 475 with mouth port 140.
- Mouth port 140 defines an opening through which a metered dose may be inhaled, from dose receiving chamber 475, by a user of MDI spacer 100.
- mouth port 140 and distal end portion may be contiguous with one another, while in other examples they may be separate pieces.
- one or more expiratory valves 135 (135-1, 135-2 visible) subcomponent(s) may be coupled with or disposed within proximal end portion 130 or mouth port 140.
- a flat portion 111 is defined by distal end portion 110 and a similar flat portion 131 is defined by proximal end portion 130.
- These flat portions 111, 131 may be positioned such that they correspond with one another to provide a base for resting MDI spacer 100, such that it does not roll around due to its otherwise substantially cylindrical shape.
- Flat portions 111, 131 may also be positioned to orient a MDI spacer 100 in a desired fashion when resting on the base formed by flat portions 111, 131.
- Figure 2 is a front left side perspective view of example MDI spacer 100, in accordance with an example.
- section indicators indicate the viewing direction of Section C - C, which is illustrated in Figure 6 .
- Figure 2 illustrates a third expiratory valve 135-3.
- Arrow 235 in Figure 2 illustrates the direction of opening of a flexible membrane of expiratory valve 135-1 in response to deflected exhaled airflow.
- MDI Metered Dose Inhaler
- Figure 3 is a detail view 150 of the distal portion of the MDI spacer of Figure 1 , in accordance with an example, and shows enlarged views of valve 112 and collar 115.
- Valve 112 is coupled with distal end portion 110 and configured for permitting external airflow into and prohibiting internal airflow out of dose receiving chamber 475.
- valve 112 combines one-way airflow control function with flow rate control of the one way air flow.
- valve 112 may only be a one-way valve or only be a flow control valve.
- the one-way airflow function of valve 112 allows air to flow in toward dose receiving chamber 475 in response to user inhalation via mouth port 140, but acts as a check valve to prevent air from flowing out of dose receiving chamber 475 via valve 112 in the event that a user exhales into mouth port 140.
- the one-way airflow functionality is provided by a flexible membrane which flexes open in response to inhaled air flow caused by user inhalation via mouth port 140. Such a membrane may return to a normally closed position in the absence of inhaled air flow (thus preventing exhaled air flow through valve 112) or flex closed against a stop in response to exhaled air flow resulting from user exhalation into mouth port 140.
- the one-way airflow function of valve 112 may also be implemented in a variety of other fashions that are known in the art.
- valve 112 allows valve 112 to limit volumetric inhalation flow through valve 112 during inhalation by a user via mouth port 140.
- a flow control function may be implemented in a variety of fashions as are known.
- One particular example of a flow control valve, which may be utilized in various examples of MDI spacer 100, is disclosed in U.S. Patent 6,681,762, to Scheuch et al. .
- Another example of an MDI spacer is disclosed in US 4 534 343 . It is appreciated that flow rate control can be configured to limit volumetric inhalation flow rate through valve 112 to a maximum volumetric airflow rate.
- valve 112 The maximum airflow rate at which valve 112 is set or designed to permit may be linked to a type of medication or to a dose size which is administered by a metered dose inhaler. It is appreciated that one-way airflow functionality may be inherent in the operation of some implementations of a flow rate control.
- Collar 115 is coupled with distal end portion 110 and configured for receiving and removably and sealably coupling with an actuator shaft of a metered dose inhaler.
- an actuator shaft is typically formed in the shape of a hollow cylindrical post which couples with an aerosol outlet of the canister of an MDI.
- a metered aerosolized dose of medicine is released from the canister into the actuator shaft and routed perpendicularly out of the aerosol nozzle that is located at the base of the actuator shaft and inside the mouthpiece of the MDI at the base of the actuator shaft.
- Curved distal edges 318 and 319 of collar 115 form a seal about the actuator shaft and sealably surround the aerosol nozzle of the MDI such that a metered dose of medication flows out of the aerosol nozzle, through the interior hollow corridor of collar 115, and into dose receiving chamber 475. At the same time, this sealing action about the actuator shaft of the MDI prohibits any other airflow into and out of dose receiving chamber 475 via collar 115. Due to this sealing of collar 115 about the actuator shaft of the MDI, during metered dose administration, valve 112 is the exclusive intake point for air inflow into MDI spacer 100 in response to inhalation via mouth port 140 by a user.
- collar 115 is disposed substantially in the center of distal end portion 110, such that a metered dose is directed via collar 115 into the center portion (of the diameter) of dose receiving chamber 475.
- collar 115 is formed of a plurality of segments such that some segments are collapsible so that the collar 115 may self-adjust in response to being coupled with an MDI.
- collar 115 is collapsible.
- Figure 3 illustrates one example collapsible configuration of collar 115 where segment 315 is fixed and segments 316 and 317 can collapse inward toward fixed segment 315 in response to pressure applied by an MDI actuator shaft being pressed against curved distal edges 318 and 319 when the mouthpiece of an MDI is inserted into opening 113.
- MDI Metered Dose Inhaler
- FIG 4 is a front right side perspective and sectional view A - A of an example MDI spacer 100 which shows an example flat velocity profile plate 450, in accordance with the invention.
- Flat velocity profile plate 450 is a subcomponent which may be included in some or all embodiments of MDI spacer 100 that are described herein.
- Flat velocity profile plate 450 is disposed within body 120 between valve 112 and dose receiving chamber 475 and forms a wall of a donut shaped inflow air receiving chamber 525 ( Figure 5 ).
- a central opening 413 is defined in flat velocity profile plate 450 and forms a portion of a sealed metered dose entrance, through collar 115, into dose receiving chamber 475.
- flat velocity profile plate includes a plurality of through holes 460 (through holes 460-1, 460-2, 460-3, 460-4, 460-5, 460-7, and 460-8 are visible in Figure 4 ) that are arranged around central opening 413. It is appreciated that a greater or lesser number of through holes 460, than are illustrated in Figure 4 , may be utilized. Through holes 460 permit passage of inflow air from inflow air receiving chamber 525 into dose receiving chamber 475.
- through holes 460 actually vary and are sized based upon respective distance from valve 112, such that each of through holes 460 provides a substantially equal air resistance (as compared with the other through holes 460) and thus normalizes air inflow velocity across the plurality of through holes 460.
- This normalization creates a flat velocity profile for inhaled air entering dose receiving chamber 475 via the plurality of through holes 460.
- through holes 460 are the only avenues for entry of air inflow into dose receiving chamber 475 in response to user inhalation via mouth port 140.
- This flat velocity profile surrounds central opening 413, which is the entry point for a metered dose of aerosolized medication.
- inhaled air inflow evenly flows through dose receiving chamber 475 at a uniform velocity, thus better mixing with aerosolized metered dose and more thoroughly sweeping the aerosolized metered dose out of dose receiving chamber 475 and into the lungs of a user than would occur in an MDI spacer which does not have a flat velocity profile for inhaled airflow.
- through holes 460 that are closer to the outlet of valve 112 into chamber 525 have a smaller diameter than through holes which are farther from the outlet of valve 112 into chamber 525. This is because the velocity of air is greater nearer the outlet of valve 112.
- diameter of a through hole 460 gets progressively larger.
- through hole 460-8 is closest to the outlet of valve 112 and therefore has the smallest diameter of any through hole 460 depicted in Figures 4 and 5 .
- Through hole 460-1 is further from the outlet of valve 112 than through hole 460-8 and is thus it is slightly larger in diameter than through hole 460-8 in order to achieve the same velocity of airflow from inflow air receiving chamber 525 to dose receiving chamber 475.
- Through hole 460-2 is further from the outlet of valve 112 than through hole 460-1 and is thus it is slightly larger in diameter than through hole 460-1 in order to achieve the same velocity of airflow from inflow air receiving chamber 525 to dose receiving chamber 475.
- other factors such as localized volume of inflow air receiving chamber 525 proximate a particular through hole 460, may affect selection of the diameter of a particular through hole. These other factors may cause a deviation from the above example where through holes 460 get progressively larger with increased distance from the outlet of valve 112 into chamber 525.
- Figure 5 is a front right side perspective and sectional view B - B of an example MDI spacer 100 which shows an example exhaled breath deflecting mechanism 520, an example flat velocity profile plate 450, and example flow paths of a metered dose 515 and inhaled breath airflow 212, in accordance with an embodiment.
- box 500 surrounds a region which is shown in enlarged detail in Figure 7 .
- central opening 413 is coupled with a proximal portion of collar 115 to form a sealed metered dose entrance through collar 115 and into dose receiving chamber.
- This sealed metered dose entrance, through collar 115, is like a tunnel that runs through inflow air receiving chamber 525, causing the volume of inflow air receiving chamber to be shaped somewhat like a donut.
- Dashed arrow 515 represents an aerosolized metered dose of medication flowing into dose receiving chamber 475 via the corridor formed within hollow collar 115.
- inhaled breath airflow 212 flows in through valve 112 and into inflow air receiving chamber 525 via valve outlet 512.
- Valve 112 restricts inhaled breath airflow 212 to a maximum flow rate which cannot be increased beyond a fixed threshold by increased user inhalation.
- Inhaled breath airflow 212 then flows into dose receiving chamber 475 at a uniform velocity through each of a plurality of through holes 460, mixes with metered dose 515, and sweeps past the conically shaped distal surface 522 of exhaled breath deflecting mechanism 520.
- distal surface 522 presents as an aerodynamic spike to air flowing toward mouth port 140. Due to this aerodynamic shape distal surface 522 offers very little resistance to air flowing toward mouth port 140, and thus discourages adhesion of particles of medication upon distal surface 522 during user inhalation via mouth port 140.
- the mixture of inhaled breath airflow 212 and metered dose 515 is represented by dashed line 565 exiting mouth port 140.
- MDI Metered Dose Inhaler
- sectional view B - B illustrates how a gap is formed between opening 113 and collar 115. This gap facilitates receipt of a mouthpiece of an MDI when collar 115 forms a seal about the actuator shaft and sealably surrounds the aerosol nozzle of the MDI.
- Sectional view B - B also illustrates the proximal surface 521 of exhaled breath deflecting mechanism 520. In the depicted embodiment, proximal surface 521 has a concave shape (e.g., the shape of the interior surface of a cone).
- proximal surface 521 may be utilized in place of the depicted proximal surface 521 in order to deflect exhaled breath toward one or more expiratory valve 135s.
- One or more supports 510 couple with exhaled breath deflecting mechanism 520 and suspend it in the manner depicted such that it is centered in an inhaled airflow path toward mouth port 140 and is also centered in an exhaled airflow path that is flowing into mouth port 140 from its proximal opening.
- Figure 6 is a front right side perspective and partial sectional view C - C of an example MDI spacer 100 which shows an example exhaled breath deflecting mechanism 520, in accordance with an embodiment.
- This embodiment gives a better view of the overall shape and positioning of exhaled breath deflecting mechanism 520 and the size of the openings which surround it and allow airflow from dose receiving chamber 475 to freely flow into mouth port 140 in response to user inhalation via mouth port 140.
- Figure 7 is a detail view 500 of a front right side perspective and sectional view B - B of an example MDI spacer 100, which shows an example exhaled breath deflecting mechanism 520 and an example flow path 740 of an exhaled breath airflow, in accordance with an embodiment.
- a user may exhale into MDI spacer 100. This is undesirable, as exhaled breath contains a high level of moisture which may cause particles of medicine in a metered dose to stick to an interior of dose receiving chamber 475, and as exhaled breath may disturb the mixing of a metered dose of medication 515 with inhaled breath airflow 212.
- exhaled breath deflecting mechanism 520 has an angled deflecting surface 521 (concave in this embodiment), which deflects exhaled airflow 740A to create deflected exhaled breath airflow 740B.
- Deflected exhaled breath airflow 740B is directed and proceeds toward the one or more expiratory valves 135 that are disposed between the proximal entry of mouth port 140 and exhaled breath deflecting mechanism 520.
- the response of expiratory valves 135-1 is representative of any other included expiratory valves 135 in MDI spacer 100.
- Membrane 735 which is fixed in place on its proximal end, is lifted (as shown by arrow 235) by the deflected exhaled airflow 740B that has been deflected by angled deflecting surface 521. Lifting of membrane 735 opens expiratory valve 135-1 and allows the exhaled airflow to escape from MDI spacer 100, as is represented by exhaled airflow 740C.
- expiratory valve 135-1 is depicted has having only a single membrane, a plurality of membranes may be employed in a similar fashion. As illustrated, expiratory valve 135-1 is operated only by deflected airflow.
- membrane 735 lifts, and thus opens expiratory valve 135-1, only in response to deflected airflow 740B which has been deflected from angled surface 521.
- Membrane 735 remains closed in response to other airflow such as: inhaled breath airflow 212, metered dose 515, mixed airflow/metered dose 565, and non-deflected exhaled airflow.
- expiratory valve(s) 135 are located outside of the airflow path of inhaled breath airflow 212, metered dose 515, and mixed airflow/metered dose 565. By locating expiratory valve(s) 135 outside of these airflow paths, expiratory valves 135 do not present targets for adhesion of medicinal particles of the metered dose during inhalation by a user of MDI spacer 100.
Description
- A Metered Dose Inhaler (MDI) is a device that, when actuated, emits a measured (metered) dose of an aerosolized medicine for inhalation by a patient. This dose of medicine is designed to be inhaled into the lungs of a user of the MDI. An MDI typically includes three portions, a canister for containing the medicine and propellant, an actuator shaft/aerosol nozzle for actuating the canister and metering out the dose, and a mouthpiece. Typically, the mouthpiece and actuator valve are combined into a single assembly into which the canister is inserted. When the canister is depressed against the actuator valve, a metered dose is emitted from the canister, through the valve and out through the mouthpiece for inhalation by a user of the MDI.
- An MDI spacer is a spacer that goes between the MDI and the mouth of a user of the MDI. An MDI spacer allows particles in the aerosolized dose to settle out a bit and mix with air, thus allowing for more effective delivery of a metered dose into a user's lungs when inhaled. An MDI spacer assists in preventing a user from inhaling the metered dose directly from an MDI where the dose would be traveling so fast that the particles of the aerosolized spray from the MDI hit and stick to the back of the user's throat rather than being inhaled into the user's lungs where the medicine of the metered dose is designed to be delivered.
- The accompanying drawings, which are incorporated in and form a part of this application, illustrate embodiments of the subject matter, and together with the description of embodiments, serve to explain the principles of the embodiments of the subject matter. Unless noted, the drawings referred to in this brief description of drawings should be understood as not being drawn to scale.
-
Figure 1 shows a rear left side perspective of an example metered dose inhaler (MDI) spacer, according to an example. -
Figure 2 is a front left side perspective view of an example MDI spacer, in accordance with an example. -
Figure 3 is a detail view of the distal portion of the MDI spacer ofFigure 1 , in accordance with an example. -
Figure 4 is a front right side perspective and sectional view of an example MDI spacer which shows an example flat velocity profile plate, in accordance with the present invention. -
Figure 5 is a front right side perspective and sectional view of an example MDI spacer which shows an example exhaled breath deflecting mechanism, an example flat velocity profile plate, and example flow paths of a metered dose and inhaled breath airflow, in accordance with an embodiment. -
Figure 6 is a front right side perspective and partial sectional view of an example MDI spacer which shows an example exhaled breath deflecting mechanism, in accordance with an embodiment. -
Figure 7 is a detail view of a front right side perspective and sectional view of an example MDI spacer which shows an example exhaled breath deflecting mechanism and an example flow path of an exhaled breath airflow, in accordance with an embodiment. - This writing broadly discloses at least a metered dose inhaler spacer having the features of claim 1.
- Reference will now be made in detail to various embodiments, examples of which are illustrated in the accompanying drawings. While the subject matter will be described in conjunction with these embodiments, it will be understood that they are not intended to limit the subject matter to these embodiments. On the contrary, the subject matter described herein is intended to cover alternatives, modifications and equivalents, which may be included within the scope of the invention which is defined by the appended claims. Furthermore, in the following description, numerous specific details are set forth in order to provide a thorough understanding of the subject matter. However, some embodiments may be practiced without these specific details. In other instances, well-known structures and components have not been described in detail as not to unnecessarily obscure aspects of the subject matter.
- Herein, various embodiments of a metered dose inhaler (MDI) spacer are described. The description will begin first with a discussion of the major structural components of an example MDI spacer. Attention will then be directed to sub-components which may be combined in various embodiments or utilized all together in an embodiment. Description of the operation of an example MDI spacer and the various components and sub-components will be further explained in conjunction with discussion of a flow path for a metered dose and inhaled breath, and description of a flow path for exhaled breath.
-
Figure 1 shows a rear left side perspective of anexample MDI spacer 100, according to an example. InFigure 1 , a first set of section indicators indicate the viewing direction of Section A - A, which is illustrated inFigure 4 ; and a second set of section indicators indicate the viewing direction of Section B - B, which is illustrated inFigures 5 and7 . - As illustrated in
Figure 1 , the major components ofMDI spacer 100 include: adistal end portion 110, abody 120, aproximal end portion 130, and amouth port 140. Subcomponents, which are described herein, may be coupled in various combinations with these major components to constitute various examples of the MDI spacers described herein. InFigure 1 ,box 150 surrounds a region which is shown in enlarged detail inFigure 3 . - Body 120 defines a dose receiving chamber 475 (
Figures 4-7 ) which acts as a spacer into which a metered dose is sprayed from an MDI prior to being inhaled into the lungs of a user ofMDI spacer 100.Body 120 is cylindrically shaped, and thedose receiving chamber 475 that is defined bybody 120 is a substantially hollow cylinder withinbody 120. -
Distal end portion 110 is coupled with a distal end (end farthest from the mouth of a user whenMDI spacer 100 is in use) ofbody 120. An opening 113 is defined indistal end portion 110.Opening 113 is sized to receive the mouthpiece of a metered dose inhaler. As will be described further below, in some embodiments, acollar 115 subcomponent may be coupled withdistal end portion 110 and disposed within opening 113. As will be further described below, a combined one-way and flow rate control valve 112 (also referred to herein as "valve 112") subcomponent is coupled withdistal end portion 110. -
Proximal end portion 130 is coupled with a proximal end (end nearest to the mouth of a user whenMDI spacer 100 is in use) ofbody 120.Proximal end portion 130 forms a proximal end of thedose receiving chamber 475.Proximal end portion 130 opens into and couplesdose receiving chamber 475 withmouth port 140.Mouth port 140 defines an opening through which a metered dose may be inhaled, fromdose receiving chamber 475, by a user ofMDI spacer 100. In some examples,mouth port 140 and distal end portion may be contiguous with one another, while in other examples they may be separate pieces. In some examples, as will be further described below, one or more expiratory valves 135 (135-1, 135-2 visible) subcomponent(s) may be coupled with or disposed withinproximal end portion 130 ormouth port 140. - In some examples, a
flat portion 111 is defined bydistal end portion 110 and a similarflat portion 131 is defined byproximal end portion 130. Theseflat portions MDI spacer 100, such that it does not roll around due to its otherwise substantially cylindrical shape.Flat portions MDI spacer 100 in a desired fashion when resting on the base formed byflat portions -
Figure 2 is a front left side perspective view ofexample MDI spacer 100, in accordance with an example. InFigure 2 , section indicators indicate the viewing direction of Section C - C, which is illustrated inFigure 6 .Figure 2 illustrates a third expiratory valve 135-3.Arrow 235 inFigure 2 illustrates the direction of opening of a flexible membrane of expiratory valve 135-1 in response to deflected exhaled airflow. -
Figure 3 is adetail view 150 of the distal portion of the MDI spacer ofFigure 1 , in accordance with an example, and shows enlarged views ofvalve 112 andcollar 115. - Valve 112 is coupled with
distal end portion 110 and configured for permitting external airflow into and prohibiting internal airflow out ofdose receiving chamber 475. In some examples,valve 112 combines one-way airflow control function with flow rate control of the one way air flow. In other examples,valve 112 may only be a one-way valve or only be a flow control valve. - The one-way airflow function of
valve 112 allows air to flow in towarddose receiving chamber 475 in response to user inhalation viamouth port 140, but acts as a check valve to prevent air from flowing out ofdose receiving chamber 475 viavalve 112 in the event that a user exhales intomouth port 140. In one example, the one-way airflow functionality is provided by a flexible membrane which flexes open in response to inhaled air flow caused by user inhalation viamouth port 140. Such a membrane may return to a normally closed position in the absence of inhaled air flow (thus preventing exhaled air flow through valve 112) or flex closed against a stop in response to exhaled air flow resulting from user exhalation intomouth port 140. The one-way airflow function ofvalve 112 may also be implemented in a variety of other fashions that are known in the art. - The flow control function of
valve 112 allowsvalve 112 to limit volumetric inhalation flow throughvalve 112 during inhalation by a user viamouth port 140. Such a flow control function may be implemented in a variety of fashions as are known. One particular example of a flow control valve, which may be utilized in various examples ofMDI spacer 100, is disclosed inU.S. Patent 6,681,762, to Scheuch et al. . Another example of an MDI spacer is disclosed inUS 4 534 343 . It is appreciated that flow rate control can be configured to limit volumetric inhalation flow rate throughvalve 112 to a maximum volumetric airflow rate. The maximum airflow rate at whichvalve 112 is set or designed to permit may be linked to a type of medication or to a dose size which is administered by a metered dose inhaler. It is appreciated that one-way airflow functionality may be inherent in the operation of some implementations of a flow rate control. -
Collar 115 is coupled withdistal end portion 110 and configured for receiving and removably and sealably coupling with an actuator shaft of a metered dose inhaler. Such an actuator shaft is typically formed in the shape of a hollow cylindrical post which couples with an aerosol outlet of the canister of an MDI. When the canister is depressed against the actuator shaft, a metered aerosolized dose of medicine is released from the canister into the actuator shaft and routed perpendicularly out of the aerosol nozzle that is located at the base of the actuator shaft and inside the mouthpiece of the MDI at the base of the actuator shaft. Curveddistal edges collar 115 form a seal about the actuator shaft and sealably surround the aerosol nozzle of the MDI such that a metered dose of medication flows out of the aerosol nozzle, through the interior hollow corridor ofcollar 115, and intodose receiving chamber 475. At the same time, this sealing action about the actuator shaft of the MDI prohibits any other airflow into and out ofdose receiving chamber 475 viacollar 115. Due to this sealing ofcollar 115 about the actuator shaft of the MDI, during metered dose administration,valve 112 is the exclusive intake point for air inflow intoMDI spacer 100 in response to inhalation viamouth port 140 by a user. - In one embodiment,
collar 115 is disposed substantially in the center ofdistal end portion 110, such that a metered dose is directed viacollar 115 into the center portion (of the diameter) ofdose receiving chamber 475. In one example,collar 115 is formed of a plurality of segments such that some segments are collapsible so that thecollar 115 may self-adjust in response to being coupled with an MDI. In some embodiments,collar 115 is collapsible.Figure 3 illustrates one example collapsible configuration ofcollar 115 wheresegment 315 is fixed andsegments segment 315 in response to pressure applied by an MDI actuator shaft being pressed against curveddistal edges opening 113. -
Figure 4 is a front right side perspective and sectional view A - A of anexample MDI spacer 100 which shows an example flatvelocity profile plate 450, in accordance with the invention. Flatvelocity profile plate 450 is a subcomponent which may be included in some or all embodiments ofMDI spacer 100 that are described herein. Flatvelocity profile plate 450 is disposed withinbody 120 betweenvalve 112 anddose receiving chamber 475 and forms a wall of a donut shaped inflow air receiving chamber 525 (Figure 5 ). - A
central opening 413 is defined in flatvelocity profile plate 450 and forms a portion of a sealed metered dose entrance, throughcollar 115, intodose receiving chamber 475. As depicted, flat velocity profile plate includes a plurality of through holes 460 (through holes 460-1, 460-2, 460-3, 460-4, 460-5, 460-7, and 460-8 are visible inFigure 4 ) that are arranged aroundcentral opening 413. It is appreciated that a greater or lesser number of through holes 460, than are illustrated inFigure 4 , may be utilized. Through holes 460 permit passage of inflow air from inflowair receiving chamber 525 intodose receiving chamber 475. - Although they may appear to be of identical diameter, the diameter sizes of through holes 460 actually vary and are sized based upon respective distance from
valve 112, such that each of through holes 460 provides a substantially equal air resistance (as compared with the other through holes 460) and thus normalizes air inflow velocity across the plurality of through holes 460. This normalization creates a flat velocity profile for inhaled air enteringdose receiving chamber 475 via the plurality of through holes 460. In one embodiment, through holes 460 are the only avenues for entry of air inflow intodose receiving chamber 475 in response to user inhalation viamouth port 140. This flat velocity profile surroundscentral opening 413, which is the entry point for a metered dose of aerosolized medication. Due to this flat velocity profile, inhaled air inflow evenly flows throughdose receiving chamber 475 at a uniform velocity, thus better mixing with aerosolized metered dose and more thoroughly sweeping the aerosolized metered dose out ofdose receiving chamber 475 and into the lungs of a user than would occur in an MDI spacer which does not have a flat velocity profile for inhaled airflow. - With respect to the variance in size, in one embodiment, through holes 460 that are closer to the outlet of
valve 112 intochamber 525 have a smaller diameter than through holes which are farther from the outlet ofvalve 112 intochamber 525. This is because the velocity of air is greater nearer the outlet ofvalve 112. Thus, in such an embodiment, as distance from the outlet ofvalve 112 increases, diameter of a through hole 460 gets progressively larger. For example, in one such embodiment, through hole 460-8 is closest to the outlet ofvalve 112 and therefore has the smallest diameter of any through hole 460 depicted inFigures 4 and5 . Through hole 460-1 is further from the outlet ofvalve 112 than through hole 460-8 and is thus it is slightly larger in diameter than through hole 460-8 in order to achieve the same velocity of airflow from inflowair receiving chamber 525 to dose receivingchamber 475. Through hole 460-2 is further from the outlet ofvalve 112 than through hole 460-1 and is thus it is slightly larger in diameter than through hole 460-1 in order to achieve the same velocity of airflow from inflowair receiving chamber 525 to dose receivingchamber 475. In some embodiments, is appreciated that other factors, such as localized volume of inflowair receiving chamber 525 proximate a particular through hole 460, may affect selection of the diameter of a particular through hole. These other factors may cause a deviation from the above example where through holes 460 get progressively larger with increased distance from the outlet ofvalve 112 intochamber 525. -
Figure 5 is a front right side perspective and sectional view B - B of anexample MDI spacer 100 which shows an example exhaledbreath deflecting mechanism 520, an example flatvelocity profile plate 450, and example flow paths of ametered dose 515 and inhaledbreath airflow 212, in accordance with an embodiment. InFigure 5 ,box 500 surrounds a region which is shown in enlarged detail inFigure 7 . - As is illustrated,
central opening 413 is coupled with a proximal portion ofcollar 115 to form a sealed metered dose entrance throughcollar 115 and into dose receiving chamber. This sealed metered dose entrance, throughcollar 115, is like a tunnel that runs through inflowair receiving chamber 525, causing the volume of inflow air receiving chamber to be shaped somewhat like a donut. - Dashed
arrow 515 represents an aerosolized metered dose of medication flowing intodose receiving chamber 475 via the corridor formed withinhollow collar 115. In response to user inhalation viamouth port 140, inhaledbreath airflow 212 flows in throughvalve 112 and into inflowair receiving chamber 525 viavalve outlet 512.Valve 112 restricts inhaledbreath airflow 212 to a maximum flow rate which cannot be increased beyond a fixed threshold by increased user inhalation. Inhaledbreath airflow 212 then flows intodose receiving chamber 475 at a uniform velocity through each of a plurality of through holes 460, mixes withmetered dose 515, and sweeps past the conically shapeddistal surface 522 of exhaledbreath deflecting mechanism 520. The conical shape ofdistal surface 522 presents as an aerodynamic spike to air flowing towardmouth port 140. Due to this aerodynamic shapedistal surface 522 offers very little resistance to air flowing towardmouth port 140, and thus discourages adhesion of particles of medication upondistal surface 522 during user inhalation viamouth port 140. The mixture of inhaledbreath airflow 212 andmetered dose 515 is represented by dashedline 565 exitingmouth port 140. - With continued reference to
Figure 5 , sectional view B - B illustrates how a gap is formed betweenopening 113 andcollar 115. This gap facilitates receipt of a mouthpiece of an MDI whencollar 115 forms a seal about the actuator shaft and sealably surrounds the aerosol nozzle of the MDI. Sectional view B - B also illustrates theproximal surface 521 of exhaledbreath deflecting mechanism 520. In the depicted embodiment,proximal surface 521 has a concave shape (e.g., the shape of the interior surface of a cone). In other embodiments, other concave shapes or even a flat surface or surfaces (e.g., the interior surfaces of a pyramid), may be utilized in place of the depictedproximal surface 521 in order to deflect exhaled breath toward one or more expiratory valve 135s. One ormore supports 510 couple with exhaledbreath deflecting mechanism 520 and suspend it in the manner depicted such that it is centered in an inhaled airflow path towardmouth port 140 and is also centered in an exhaled airflow path that is flowing intomouth port 140 from its proximal opening. -
Figure 6 is a front right side perspective and partial sectional view C - C of anexample MDI spacer 100 which shows an example exhaledbreath deflecting mechanism 520, in accordance with an embodiment. This embodiment gives a better view of the overall shape and positioning of exhaledbreath deflecting mechanism 520 and the size of the openings which surround it and allow airflow fromdose receiving chamber 475 to freely flow intomouth port 140 in response to user inhalation viamouth port 140. -
Figure 7 is adetail view 500 of a front right side perspective and sectional view B - B of anexample MDI spacer 100, which shows an example exhaledbreath deflecting mechanism 520 and an example flow path 740 of an exhaled breath airflow, in accordance with an embodiment. Occasionally, a user may exhale intoMDI spacer 100. This is undesirable, as exhaled breath contains a high level of moisture which may cause particles of medicine in a metered dose to stick to an interior ofdose receiving chamber 475, and as exhaled breath may disturb the mixing of a metered dose ofmedication 515 with inhaledbreath airflow 212. - To assist in preventing exhaled breath 740 from encroaching into
dose receiving chamber 475, exhaledbreath deflecting mechanism 520 has an angled deflecting surface 521 (concave in this embodiment), which deflects exhaledairflow 740A to create deflected exhaledbreath airflow 740B. Deflected exhaledbreath airflow 740B is directed and proceeds toward the one or more expiratory valves 135 that are disposed between the proximal entry ofmouth port 140 and exhaledbreath deflecting mechanism 520. InFigure 7 , the response of expiratory valves 135-1 is representative of any other included expiratory valves 135 inMDI spacer 100.Membrane 735, which is fixed in place on its proximal end, is lifted (as shown by arrow 235) by the deflectedexhaled airflow 740B that has been deflected by angled deflectingsurface 521. Lifting ofmembrane 735 opens expiratory valve 135-1 and allows the exhaled airflow to escape fromMDI spacer 100, as is represented by exhaledairflow 740C. Although expiratory valve 135-1 is depicted has having only a single membrane, a plurality of membranes may be employed in a similar fashion. As illustrated, expiratory valve 135-1 is operated only by deflected airflow. This is becausemembrane 735 lifts, and thus opens expiratory valve 135-1, only in response to deflectedairflow 740B which has been deflected fromangled surface 521.Membrane 735 remains closed in response to other airflow such as: inhaledbreath airflow 212,metered dose 515, mixed airflow/metereddose 565, and non-deflected exhaled airflow. Additionally, because of this indirect actuation, expiratory valve(s) 135 are located outside of the airflow path of inhaledbreath airflow 212,metered dose 515, and mixed airflow/metereddose 565. By locating expiratory valve(s) 135 outside of these airflow paths, expiratory valves 135 do not present targets for adhesion of medicinal particles of the metered dose during inhalation by a user ofMDI spacer 100. - The foregoing descriptions of specific embodiments have been presented for purposes of illustration and description. They are not intended to be exhaustive or to limit the presented technology to the precise forms disclosed, and obviously many modifications and variations are possible in light of the above teaching. The figures and embodiments were chosen and described in order to best explain the principles of the presented technology and its practical application, to thereby enable others skilled in the art to best utilize the presented technology and various embodiments with various modifications as are suited to the particular use contemplated. While the subject matter has been described in particular embodiments, it should be appreciated that the subject matter should not be construed as limited by such embodiments, but rather construed according to the following claims.
- All elements, parts and steps described herein are preferably included. It is to be understood that any of these elements, parts and steps may be replaced by other elements, parts and steps or deleted altogether as will be obvious to those skilled in the art.
- This writing discloses at least the following concepts.
- Concept 1. A metered dose inhaler (MDI) spacer comprising:
- a body that defines a dose receiving chamber;
- a proximal end portion coupled with said body;
- a mouth port coupled with said proximal end portion and through which a metered dose may be inhaled by a user of said MDI spacer;
- a distal end portion coupled with said body;
- a combined one-way and flow rate control valve coupled with said distal end portion and configured for permitting external airflow into and prohibiting internal airflow out of said dose receiving chamber; and
- a collar coupled with said distal end portion and configured for receiving an actuator shaft of a metered dose inhaler and for forming a seal about an aerosol nozzle of said metered dose inhaler such that a metered dose of medication is admissible into said dose receiving chamber via said collar while airflow into and out of said dose receiving chamber via said collar is prohibited.
- Concept 2. The MDI spacer of Concept 1, wherein said collar is collapsible.
- Concept 3. The MDI spacer of Concept 1, wherein said collar is substantially centered in said distal end portion.
- Concept 4. The MDI spacer of Concept 1, wherein said combined one-way and flow rate control valve is an exclusive intake point for air inflow into said MDI spacer in response to inhalation via said mouth port by said user during metered dose inhalation.
- Concept 5. The MDI spacer of Concept 1, further comprising:
a flat velocity profile plate disposed within said body between said combined one-way and flow rate control valve and said dose receiving chamber to form a wall of a donut shaped inflow air receiving chamber, wherein a central opening defined in said flat velocity profile plate is coupled with said collar to form a sealed metered dose entrance through said collar and into said dose receiving chamber. - Concept 6. The MDI spacer of Concept 5, wherein said flat velocity profile plate comprises a plurality of through holes arranged around said central opening, said through holes for permitting passage of inflow air from said inflow air receiving chamber into said dose receiving chamber.
- Concept 7. The MDI spacer of Concept 6, wherein diameter sizes of said through holes are sized based upon respective distances from said combined one-way and flow rate control valve such that each of said through holes provides a substantially equal air resistance and thus normalizes air inflow velocity across said plurality of through holes to create a flat velocity profile for inhaled air entering said dose receiving chamber.
- Concept 8. A metered dose inhaler (MDI) spacer comprising:
- a body that defines a dose receiving chamber;
- a proximal end portion coupled with said body;
- a mouth port coupled with said proximal end portion and through which a metered dose may be inhaled by a user of said MDI spacer;
- a distal end portion coupled with said body;
- a combined one-way and flow rate control valve coupled with said distal end portion and configured for permitting external airflow into and prohibiting internal airflow out of said dose receiving chamber; and
- a flat velocity profile plate disposed within said body between said combined one-way and flow rate control valve and said dose receiving chamber.
- Concept 9. The MDI spacer of Concept 8, wherein said flat velocity profile plate forms a wall of a donut shaped inflow air receiving chamber.
- Concept 10. The MDI spacer of Concept 8, wherein in a central opening defined in said flat velocity profile plate forms a portion of a sealed metered dose entrance into said dose receiving chamber.
- Concept 11. The MDI spacer of Concept 10, wherein said flat velocity profile plate comprises a plurality of through holes arranged around said central opening, said through holes for permitting passage of inflow air from said inflow air receiving chamber into said dose receiving chamber.
- Concept 12. The MDI spacer of Concept 8, wherein diameter sizes of said through holes are sized based upon respective distances from said combined one-way and flow rate control valve such that each of said through holes provides a substantially equal air resistance and thus normalizes air inflow velocity across said plurality of through holes to create a flat velocity profile for inhaled air entering said dose receiving chamber.
- Concept 13. A metered dose inhaler (MDI) spacer comprising:
- a body that defines a dose receiving chamber;
- a proximal end portion coupled with said body;
- a mouth port coupled with said proximal end portion and through which a metered dose may be inhaled from said dose receiving chamber by a user of said MDI spacer; and
- an expiratory valve; and
- an exhaled breath deflecting mechanism coupled with said mouth port in an exhaled breath airflow path and configured for deflecting exhaled breath airflow, received via said mouth port, out of said MDI spacer via said expiratory valve.
- Concept 14. The MDI spacer of Concept 13, further comprising a plurality of expiratory valves coupled with said proximal end portion.
- Concept 15. The MDI spacer of Concept 13, wherein said expiratory valve is configured to open only in response to deflected exhaled breath airflow.
- Concept 16. The MDI spacer of Concept 13, wherein said exhaled breath deflecting mechanism comprises:
- a concave exhaled breath airflow reflecting surface; and
- a conical surface exposed to inhaled breath airflow.
- Concept 17. A metered dose inhaler (MDI) spacer comprising:
- a body that defines a dose receiving chamber;
- a distal end portion coupled with said body;
- a combined one-way and flow rate control valve coupled with said distal end portion and configured for permitting external airflow into and prohibiting internal airflow out of said dose receiving chamber;
- a collar coupled with said distal end portion and configured for receiving an actuator shaft of a metered dose inhaler and for forming a seal about an aerosol nozzle of said metered dose inhaler such that a metered dose of medication is admissible into said dose receiving chamber via said collar while airflow into and out of said dose receiving chamber via said collar is prohibited;
- a flat velocity profile plate disposed within said body between said combined one-way and flow rate control valve and said dose receiving chamber to form a wall of an inflow air receiving chamber;
- a proximal end portion coupled with said body;
- a mouth port through which a metered dose may be inhaled from said dose receiving chamber by a user of said MDI spacer;
- an expiratory valve; and
- an exhaled breath deflecting mechanism coupled with said mouth port in an exhaled breath airflow path and configured for deflecting exhaled breath airflow, received via said mouth port, out of said MDI spacer via said expiratory valve.
- Concept 18. The MDI spacer of Concept 17, wherein said collar is collapsible.
- Concept 19. The MDI spacer of Concept 17, wherein said collar is substantially centered in said distal end portion.
- Concept 20. The MDI spacer of Concept 17, wherein said combined one-way and flow rate control valve is an exclusive intake point for air inflow into said MDI spacer in response to inhalation via said mouth port by said user during metered dose inhalation.
- Concept 21. The MDI spacer of Concept 17, wherein a central opening defined in said flat velocity profile plate is coupled with said collar to form a sealed metered dose entrance through said collar and into said dose receiving chamber.
- Concept 22. The MDI spacer of Concept 21, wherein said flat velocity profile plate comprises a plurality of through holes arranged around said central opening, said through holes for permitting passage of inflow air from said inflow air receiving chamber into said dose receiving chamber, wherein diameter sizes of said through holes are sized based upon respective distances from said combined one-way and flow rate control valve such that each of said through holes provides a substantially equal air resistance and thus normalizes air inflow velocity across said plurality of through holes to create a flat velocity profile for inhaled air entering said dose receiving chamber.
- Concept 23. The MDI spacer of Concept 17, wherein said expiratory valve is configured to open only in response to deflected exhaled breath airflow.
- Concept 24. The MDI spacer of Concept 17, wherein said exhaled breath deflecting mechanism comprises:
- a concave exhaled breath airflow reflecting surface; and
- a conical surface exposed to inhaled breath airflow.
Claims (9)
- A metered dose inhaler (MDI) spacer comprising:a body (120) that defines a dose receiving chamber (475);a proximal end portion (130) coupled with said body (120);a mouth port (140) coupled with said proximal end portion (130)and through which a metered dose may be inhaled by a user of said MDI spacer;a distal end portion (110) coupled with said body (120);a combined one-way and flow rate control valve (112) coupled with said distal end portion (110) and configured for permitting external airflow into said dose receiving chamber (475) and prohibiting internal airflow out of said dose receiving chamber from said distal end portion (110); anda collar (115) coupled with said distal end portion (110) and configured for receiving an actuator shaft of a metered dose inhaler and for forming a seal about an aerosol nozzle of said metered dose inhaler such that a metered dose of medication is admissible into said dose receiving chamber via said collar (115) while airflow into and out of said dose receiving chamber (475) via said collar (115) is prohibited characterized by
a flat velocity profile plate (450) disposed within said body (120) between said combined one-way and flow rate control valve(112) and said dose receiving chamber (475) to form a wall of a donut shaped inflow air receiving chamber,wherein a central opening (413) in said flat velocity profile plate (450) is coupled with said collar (115) to form a sealed metered dose entrance through said collar (115) and into said dose receiving chamber (475), and wherein said flat velocity profile plate (450) comprises a plurality of through holes (460) arranged around said central opening (413), said through holes permitting passage of inflow air from inflow air receiving chamber (525) into said dose receiving chamber (475). - The MDI spacer of Claim 1, wherein said collar (115) is collapsible.
- The MDI spacer of Claim 1, wherein said collar (115)is substantially centered in said distal end portion (110).
- The MDI spacer of Claim 1, wherein said combined one-way and flow rate control valve (112) is an exclusive intake point for air inflow into said MDI spacer in response to inhalation via said mouth port (140) by said user during metered dose inhalation.
- The MDI spacer of Claim 1, wherein diameter sizes of said through holes (460) are sized based, upon respective distances from said combined, one-way and flow rate control valve such that each of said through holes provides a substantially equal air resistance and thus normalizes air inflow velocity across said plurality of through holes to create a flat velocity profile for inhaled air entering said dose receiving chamber (475) .
- The MDI spacer of claim 1, further comprising
an expiratory valve (135); and
an exhaled breath deflecting mechanism (520) coupled with said mouth port (140) in an exhaled breath airflow path and configured for deflecting exhaled breath airflow, received via said mouth port, out of said MDI spacer via said expiratory valve (135). - The MDI spacer of Claim 6, further comprising a plurality of expiratory valves (135) coupled with said proximal end portion (130).
- The MDI spacer of Claim 6, wherein said expiratory valve (135) is configured to open only in response to deflected exhaled breath airflow.
- The MDI spacer of Claim 6, wherein said exhaled breath deflecting mechanism (520) comprises:a concave exhaled breath airflow reflecting surface (521); anda conical surface exposed to inhaled breath airflow.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/077,849 US8770188B2 (en) | 2011-03-31 | 2011-03-31 | Metered dose inhaler spacer |
PCT/US2012/030470 WO2012135072A2 (en) | 2011-03-31 | 2012-03-23 | Metered dose inhaler spacer |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2691135A2 EP2691135A2 (en) | 2014-02-05 |
EP2691135A4 EP2691135A4 (en) | 2015-02-18 |
EP2691135B1 true EP2691135B1 (en) | 2018-09-19 |
Family
ID=46925593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12763707.2A Not-in-force EP2691135B1 (en) | 2011-03-31 | 2012-03-23 | Metered dose inhaler spacer |
Country Status (4)
Country | Link |
---|---|
US (1) | US8770188B2 (en) |
EP (1) | EP2691135B1 (en) |
ES (1) | ES2702764T3 (en) |
WO (1) | WO2012135072A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2618876B1 (en) * | 2010-09-21 | 2018-11-14 | Koninklijke Philips N.V. | Valved holding chamber including valve retention system |
USD735316S1 (en) * | 2013-03-11 | 2015-07-28 | Fsc Laboratories, Inc. | Inhalation spacer |
US9993603B2 (en) * | 2015-08-17 | 2018-06-12 | George Ashford Reed | Valved medical aerosol holding and delivery chamber |
EP3432954B1 (en) | 2016-03-24 | 2022-04-20 | Services Medicaux Arnold et Joan Zidulka Inc. | Device for delivering particles in the upper respiratory tract |
USD861855S1 (en) * | 2016-05-04 | 2019-10-01 | R. Cegla Gmbh & Co. Kg | Inhaler |
USD855173S1 (en) * | 2016-05-04 | 2019-07-30 | R. Cegla Gmbh & Co. Kg | Inhaler |
USD851746S1 (en) * | 2016-06-08 | 2019-06-18 | Pari GmbH Spezialisten für effektive Inhalation | Spacer chamber for an inhaler |
USD820433S1 (en) * | 2016-06-08 | 2018-06-12 | Pari GmbH Spezialisten für effektive Inhalation | Spacer chamber with actuator for an inhaler |
USD835260S1 (en) * | 2017-04-06 | 2018-12-04 | Abithas, Llc | Delivery assist device for metered dose inhaler |
US11504488B2 (en) | 2017-07-07 | 2022-11-22 | Paul G. Andrus | Dilution spacer and method for metered-dose inhaler |
US10052445B1 (en) * | 2017-07-07 | 2018-08-21 | Paul G. Andrus | Dilution spacer and method for metered-dose inhaler |
WO2019236662A1 (en) * | 2018-06-05 | 2019-12-12 | Teleflex Medical Incorporated | Valved spacer for inhalation device |
EP3693044A1 (en) * | 2019-02-07 | 2020-08-12 | Koninklijke Philips N.V. | Breath actuated inhalers |
EP3952960A4 (en) * | 2019-04-12 | 2023-01-04 | National University of Singapore | Inhalable medical aerosol dispensing system |
JP1700983S (en) * | 2021-06-23 | 2021-11-29 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3994421A (en) * | 1975-09-29 | 1976-11-30 | American Cyanamid Company | Unitary therapeutic aerosol dispenser |
US4470412A (en) * | 1982-03-19 | 1984-09-11 | Trutek Research, Inc. | Inhalation valve |
US4534343A (en) * | 1984-01-27 | 1985-08-13 | Trutek Research, Inc. | Metered dose inhaler |
GB8908647D0 (en) * | 1989-04-17 | 1989-06-01 | Glaxo Group Ltd | Device |
US5042467A (en) * | 1990-03-28 | 1991-08-27 | Trudell Medical | Medication inhaler with fitting having a sonic signalling device |
DE4208880A1 (en) * | 1992-03-19 | 1993-09-23 | Boehringer Ingelheim Kg | SEPARATOR FOR POWDER INHALATORS |
US5848588A (en) | 1994-05-25 | 1998-12-15 | Trudell Medical Group | Backpiece for receiving an MDI adapter in an aerosolization spacer |
AUPN417395A0 (en) | 1995-07-14 | 1995-08-10 | Techbase Pty. Ltd. | An improved spacer |
US5738087A (en) * | 1995-09-21 | 1998-04-14 | King; Russell W. | Aerosol medication delivery system |
US6293279B1 (en) | 1997-09-26 | 2001-09-25 | Trudell Medical International | Aerosol medication delivery apparatus and system |
US6039042A (en) | 1998-02-23 | 2000-03-21 | Thayer Medical Corporation | Portable chamber for metered dose inhaler dispensers |
US6681768B2 (en) * | 2001-06-22 | 2004-01-27 | Sofotec Gmbh & Co. Kg | Powder formulation disintegrating system and method for dry powder inhalers |
US6595206B2 (en) * | 2001-07-13 | 2003-07-22 | John Vito | Extendable spacer device and metered dose inhaler |
US7748385B2 (en) * | 2003-05-23 | 2010-07-06 | Ric Investments, Inc | Valved holding chamber for use with an aerosol medication delivery system |
US8151794B2 (en) * | 2007-04-24 | 2012-04-10 | Trudell Medical International | Aerosol delivery system |
WO2010008424A2 (en) * | 2008-04-04 | 2010-01-21 | Novartis Ag | Aerosolization device |
-
2011
- 2011-03-31 US US13/077,849 patent/US8770188B2/en not_active Expired - Fee Related
-
2012
- 2012-03-23 EP EP12763707.2A patent/EP2691135B1/en not_active Not-in-force
- 2012-03-23 ES ES12763707T patent/ES2702764T3/en active Active
- 2012-03-23 WO PCT/US2012/030470 patent/WO2012135072A2/en unknown
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
WO2012135072A2 (en) | 2012-10-04 |
EP2691135A2 (en) | 2014-02-05 |
US20120247460A1 (en) | 2012-10-04 |
EP2691135A4 (en) | 2015-02-18 |
ES2702764T3 (en) | 2019-03-05 |
US8770188B2 (en) | 2014-07-08 |
WO2012135072A3 (en) | 2013-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2691135B1 (en) | Metered dose inhaler spacer | |
US20200282174A1 (en) | Modular pulmonary treatment system | |
US5617844A (en) | Aerosol medication delivery system | |
US5522380A (en) | Metered dose medication adaptor with improved incentive spirometer | |
US5738087A (en) | Aerosol medication delivery system | |
US20200360641A1 (en) | Modular pulmonary treatment system | |
RU2188041C2 (en) | Method and device for spraying medicaments | |
EP0692990B1 (en) | Deagglomerators for dry powder inhalers | |
US20170056609A1 (en) | Enhanced eductor design | |
US7748385B2 (en) | Valved holding chamber for use with an aerosol medication delivery system | |
US7493898B2 (en) | Inhalation apparatus | |
US20160339187A1 (en) | Devices and methods for controlled drug delivery of wet aerosols | |
PT1804871E (en) | An improved spacer | |
GB2490770A (en) | Adapter to indicate correct air flow rate through an inhalator | |
RU2757077C2 (en) | Device for the administration of inhaled drugs in the form of dry powder with dosing resistance mechanism through replaceable nozzles | |
CA2658095A1 (en) | Fluid flow regulating device | |
US11179525B2 (en) | Inhaler adapter for patient breathing tube assembly and method | |
US20160367770A1 (en) | Oral inhaler mixer system and method | |
US20200261668A1 (en) | An actuator housing for a metered dose inhaler device | |
CA2210721C (en) | Metered dose medication adaptor with improved incentive spirometer | |
US11577033B2 (en) | Valved spacer for inhalation device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20131025 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20150119 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61M 5/168 20060101ALI20150113BHEP Ipc: A61M 39/22 20060101ALI20150113BHEP Ipc: A61M 15/00 20060101AFI20150113BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61M 15/00 20060101AFI20180321BHEP |
|
INTG | Intention to grant announced |
Effective date: 20180424 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1042522 Country of ref document: AT Kind code of ref document: T Effective date: 20181015 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012051305 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20180919 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181220 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181219 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181219 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2702764 Country of ref document: ES Kind code of ref document: T3 Effective date: 20190305 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1042522 Country of ref document: AT Kind code of ref document: T Effective date: 20180919 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190119 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190119 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012051305 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 |
|
26N | No opposition filed |
Effective date: 20190620 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190323 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20190331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190331 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190331 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190323 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20200221 Year of fee payment: 9 Ref country code: DE Payment date: 20200218 Year of fee payment: 9 Ref country code: IT Payment date: 20200218 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190323 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20200220 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20200401 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20120323 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602012051305 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20210323 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210331 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210323 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211001 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210323 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20220524 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180919 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210324 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20230427 AND 20230503 |